Profound geroprotection from brief rapamycin treatment in early adulthood by persistently increased intestinal autophagy
P. Juricic, Y.-X. Lu, T. Leech, L. F. Drews, J. Paulitz, J. Lu, T. Nespital, S. Azami, J. C. Regan, E. Funk, J. Fröhlich, S. Grönke, L. Partridge
Abstract
The licensed drug rapamycin has potential to be repurposed for geroprotection. A key challenge is to avoid adverse side-effects from continuous dosing regimes. Here we show a profound memory effect of brief, early rapamycin treatment of adults, which extended lifespan in Drosophila to the same degree as lifelong dosing. Lasting memory of earlier rapamycin treatment was mediated by elevated autophagy in enterocytes of the gut, accompanied by increased levels of intestinal lysosomal alpha-mannosidase V (LManV), proteins involved in branched-chain amino acid metabolism and lysozyme levels, and by maintained structure and function of the ageing intestine. Brief elevation of autophagy in early adulthood itself induced a long-term increase in autophagy. In mice, a short-term, 3-month treatment in early adulthood also induced a memory effect, with maintenance similar to that seen with chronic treatment, of lysozyme distribution, Man2B1 level in intestinal crypts, Paneth cell architecture and gut barrier function, even 6 months after rapamycin was withdrawn. The geroprotective effects of chronic rapamycin treatment can thus be obtained with a brief pulse of the drug in early adulthood.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Sexual identity of enterocytes regulates rapamycin-mediated intestinal homeostasis and lifespan extension
J. C. Regan, Y.-X. Lu, … L. Partridge·bioRxiv·Oct 22, 2021
- Rapamycin alters the feeding preference for amino acids and sugar in female Drosophila
Guixiang Yu, Qihao Yang, Qi Wu·The Journals of Gerontology Series APeer-reviewed·Apr 23, 2025
- Long-term rapamycin treatment suppresses IL-17-producing gamma delta T cells and blunts neuroinflammation in aging
Clement Torrent, Caterina Gagliardi, … Lily Keane·PLoS ONEPeer-reviewed·May 28, 2026
- A combination of the geroprotectors trametinib and rapamycin is more effective than either drug alone
Lisonia Gkioni, Tobias Nespital, … Linda Partridge·Nature AgingPeer-reviewed·May 28, 2025
- Deficient autophagy drives aging in Hydra
Szymon Tomczyk, Quentin Schenkelaars, … Brigitte Galliot·bioRxiv·Dec 23, 2017
- Rapamycin treatment during development extends lifespan and healthspan
Anastasia V. Shindyapina, Yongmin Cho, … Vadim N. Gladyshev·bioRxiv·Feb 18, 2022